Canadian AI pioneer Zentrela is announcing this week the results of a groundbreaking study it conducted with Kinloch Wellness, a leader in non-psychoactive, plant-based health and wellness products.
In the research from the two companies, the organizations looked to objectively quantify the efficacy of Kinloch’s Serene™ CBD Green Apple Drop using Zentrela’s EEG brainwave analysis tool, called the Cognalyzer®, in order to gather a detailed understanding of the relaxation effects on participants.
This EEG-based study was the first of its kind to objectively quantify how effective a CBD-only product is at increasing the relaxation state of consumers.
In fact, what the Canadian companies found is that the gummies from Kinloch were 3X more effective in producing a relaxing effect in females than in males.
According to a press release this week from the organizations, 1 gummy was optimal for females, however males were likely to require a higher dose to receive a similar level of relaxation, highlighting the importance of conducting the unexpected results that may arise as Zentrela’s products make brainwave analysis more accessible and affordable.
The research may also help to justify future investigations that explore how CBD products are used by women to treat specific conditions such as menopause. To learn more about the study, visit here.
Said Israel Gasperin, CEO of Zentrela, “The study with Kinloch has shown how CBD can impact the genders very differently. Having access to detailed data insights like this will help to inform a safer future for CBD users and an industry built on high-quality products.”
Kinloch as a company is looking to address the current void in CBD product information by introducing standardized efficacy insights for consumers. While product packaging details ingredient composition, it fails to quantify product effects, which hinders consumers’ ability to make informed purchasing decisions.
Added Dwayne Stewart, Kinloch Wellness’ CEO, “Zentrela has allowed us to give data-based insights into the performance of our products for both medical professionals and recreational sellers of our products, enhancing their access to information about how our products may perform for their patients and clients.”
Zentrela was founded in Canada by Engineering Scientist and entrepreneur Israel Gasperin with the support of Dr. Dan Bosnyak, a University of McMaster neuroscientist.
The company offers a commercially viable way to objectively quantify the psychoactive effects of cannabis, with its Cognalyzer® solution being a portable non-invasive device that scans brainwaves using AI and wearable EEG technology.
